Compare Pfizer Inc (PFE) vs Sherwin-Williams Company (The) Common Stock (SHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Sherwin-Williams Company (The) Common Stock — how do they compare? Pfizer Inc trades at $29.35 (market cap $161.70B), while Sherwin-Williams Company (The) Common Stock trades at $326.76 (market cap $78.68B). The key difference: Pfizer Inc is far larger — about 2.1× Sherwin-Williams Company (The) Common Stock's market cap, and Pfizer Inc pays the higher dividend (6.06%). Which is the better fit depends on your goals.
| PFE | SHW | |
|---|---|---|
Market Cap | $161.70B | $78.68B |
Volume | 26,828,084 | 1,245,324 |
Sector | Health | Basic Materials |
52-Week High | $29.21 | $372.60 |
52-Week Low | $23.67 | $293.00 |
Typical Hold Time | 158 Days | — |
Enterprise Value | $213.20B | $92.60B |
Dividend Yield | 6.06% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.40, up 0.42% with a bullish technical signal from moving averages. The company maintains strong profitability with a 73.18% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights Pfizer's focus on AI drug discovery and a catalyst-rich pipeline in obesity and oncology for 2026, while analysts maintain a mixed consensus with 40% buy ratings.
Pfizer presents a balanced opportunity with stable cash flows and dividend payments, but faces headwinds from patent cliffs and declining net income margins. The stock trades near analyst consensus targets with moderate upside potential, though execution risks in pipeline development and competitive pressures warrant caution for growth-oriented investors.
Sherwin-Williams (SHW) trades at $324.10, up 1.21% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals but maintains robust fundamentals with 65.12% ROE and expanding manufacturing capacity. Recent facility expansions in Statesville enhance production capabilities, positioning the company for continued market share gains.
Outlook remains positive with analyst consensus at Buy (57.9%) and $383.64 price target, though high valuation multiples (P/E 29.9) and competitive pressures present risks. Earnings growth and strategic investments support upside potential, while margin compression and economic sensitivity warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Sherwin-Williams Company (The) Common Stock
The Sherwin-Williams Company manufactures, develops, and distributes paints, coatings, and related products through three segments: Paint Stores Group, operating more than 4,900 company-owned stores selling Sherwin-Williams-branded products; Consumer Brands Group, selling brands such as Valspar, Dutch Boy, Krylon, and Minwax through mass merchandisers and home centers; and Performance Coatings Group, supplying industrial, construction, and transportation coatings in more than 120 countries.
Read more on SHW →
